



THE UNIVERSITY OF ARIZONA
COLLEGE OF MEDICINE TUCSON

Department
of Medicine


Medicine Grand Rounds

“Inflammatory Bowel Diseases – Poster child for precision medicine beyond oncology?”

Speaker: **Dermot McGovern MD, PhD, FRCP, FACC, AGAF**

UArizona College of Medicine – Tucson
Lecture Hall, Room 5403
1501 N. Campbell Ave., Tucson, AZ 85721
Noon – 1:00 pm | Wednesday, Nov. 8, 2023

About the Presenter: Dr. McGovern earned his medical degree from St. Mary's Hospital Medical School, Imperial College, University of London, and did his residency at Gloucester Royal Hospital in Gloucester, England. He completed his gastroenterology fellowship and obtained a doctorate in complex disease genetics at the University of Oxford before moving to Los Angeles' Cedars-Sinai Medical Center more than a decade ago. There, he's director of translational medicine at the F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute as well as the Cedars-Sinai Precision Medicine Initiative. A professor of medicine at the David Geffen School of Medicine at UCLA, he holds the Joshua and Lisa Greer Endowed Chair in IBD Genetics. His clinical interests include extra-intestinal complications of IBD and also the overlap between IBD and other immune-mediated and metabolic diseases. Dr. McGovern serves on the National Scientific Advisory Committee for the Crohn's and Colitis Foundation as well as the steering committees of the National and International IBD Genetics Consortia. He also chairs the CCFA local advisory medical committee. In addition, he serves on the editorial board for the IBD Journal. He has been elected a member of the American Society for Clinical Investigation and also the International Organization for the Study of IBD. Dr. McGovern's group is funded by the NIH as well as the Crohn's and Colitis Foundation, The Litwin Foundation and the Helmsley Charitable Trust to study the effect of genetics on susceptibility to and natural history of IBD in diverse populations. His group analyzes multi-omic datasets to identify potential biomarkers and therapeutic targets of IBD that 'feed' the drug development Unit he co-directs. This group also has a significant interest in pharmacogenetics of therapies used in IBD and extending these studies to diverse populations including African Americans, Hispanics, and the Ashkenazi Jewish population is a major focus of his group. The group has published about 150 peer-reviewed papers in journals including Nature, Science, Cell, Nature Genetics, The Lancet, and Gastroenterology.



Livestream link: <https://streaming.biocom.arizona.edu/streaming/30418/event>

Zoom link: <https://arizona.zoom.us/j/83633948595>

For questions or accommodations that may be necessary, please contact the Office of the Chair, 520-626-6349.